INAF Stock Overview
Manufactures and sells pharmaceutical products in Indonesia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PT Indofarma Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp126.00 |
| 52 Week High | Rp725.00 |
| 52 Week Low | Rp126.00 |
| Beta | -0.042 |
| 11 Month Change | -1.56% |
| 3 Month Change | -3.08% |
| 1 Year Change | -80.47% |
| 33 Year Change | -95.25% |
| 5 Year Change | -94.32% |
| Change since IPO | -38.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| INAF | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | -1.2% |
| 1Y | -80.5% | -18.1% | 9.4% |
Return vs Industry: INAF underperformed the ID Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: INAF underperformed the ID Market which returned 9.4% over the past year.
Price Volatility
| INAF volatility | |
|---|---|
| INAF Average Weekly Movement | 12.5% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in ID Market | 12.8% |
| 10% least volatile stocks in ID Market | 2.9% |
Stable Share Price: INAF's share price has been volatile over the past 3 months.
Volatility Over Time: INAF's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of ID stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1918 | 1,086 | . Yeliandriani | indofarma.id |
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutical, and medical equipment; and engages in herb infusion, health support, private polyclinic, general practitioner, dentist, and internet trading applications activities.
PT Indofarma Tbk Fundamentals Summary
| INAF fundamental statistics | |
|---|---|
| Market cap | Rp390.51b |
| Earnings (TTM) | -Rp720.99b |
| Revenue (TTM) | Rp523.60b |
0.7x
P/S Ratio-0.5x
P/E RatioIs INAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INAF income statement (TTM) | |
|---|---|
| Revenue | Rp523.60b |
| Cost of Revenue | Rp687.88b |
| Gross Profit | -Rp164.28b |
| Other Expenses | Rp556.72b |
| Earnings | -Rp720.99b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -232.63 |
| Gross Margin | -31.37% |
| Net Profit Margin | -137.70% |
| Debt/Equity Ratio | -86.9% |
How did INAF perform over the long term?
See historical performance and comparison